Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 7,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Type 2 Diabetes
Interventions: A1C Drink, Placebo drink; Dietary Supplement · Other
Lead sponsor: University of California, Riverside; Other
Eligibility: 21 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Riverside, California

Conditions: Hypertension
Interventions: nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 75
States / cities: Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more

Conditions: Acute Ischemic Stroke
Interventions: natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 19
States / cities: San Diego, California • Gainesville, Florida • Kansas City, Kansas + 16 more

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: Placebo, 375 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 40 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more

Conditions: Metabolic Syndrome, Hypertension
Interventions: 14 Nitrogen (N) Sodium Nitrite, Placebo; Drug
Lead sponsor: Gladwin, Mark, MD; Individual
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Stress, Emotional, Sleep Disturbance
Interventions: Sleep Hygiene Intervention, Non-behavioral Sleep Education; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Crohn's Disease
Interventions: Andecaliximab, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 33
States / cities: Dothan, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more

Conditions: Healthy Participants
Interventions: TAK-994, TAK-994 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Glendale, California • Salt Lake City, Utah

Conditions: Pulmonary Embolism, COVID
Interventions: TNKase, Placebo, Enoxaparin; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-alcoholic Fatty Liver Disease, Obesity
Interventions: BI 3006337, Placebo matching BI 3006337; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 12
States / cities: Chula Vista, California • La Mesa, California • Montclair, California + 8 more

Conditions: Asthma
Interventions: Vapendavir, Placebo; Drug
Lead sponsor: Biota Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Bakersfield, California + 30 more

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Tempe, Arizona • Encino, California • Fresno, California + 24 more

Conditions: Acute Coronary Syndrome
Interventions: Dalcetrapib, Placebo; Drug
Lead sponsor: DalCor Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 186
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more

Conditions: Stroke
Interventions: SUN13837, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 37
States / cities: Mobile, Alabama • Encinita, California • Oceanside, California + 29 more

Conditions: Friedreich Ataxia
Interventions: TAK-831, TAK-831 Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 3 more

Conditions: Adults With Overweight/Obesity and Type 2 Diabetes
Interventions: AT673 low dose, AT673 high dose, Placebo; Drug
Lead sponsor: Antag Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Chandler, Arizona • Anaheim, California • Hollywood, Florida + 5 more

Conditions: Healthy
Interventions: AZD1613, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Influenza
Interventions: mRNA-1018-H5, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: San Bernardino, California • Savannah, Georgia • Meridian, Idaho + 7 more

Conditions: Healthy Volunteers
Interventions: Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules; Dietary Supplement
Lead sponsor: Jacksonville State University; Other
Eligibility: 18 Weeks to 40 Weeks
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Jacksonville, Alabama

Conditions: Chronic Constipation
Interventions: Linaclotide 290 micrograms, Linaclotide 145 micrograms, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 100
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 89 more

Conditions: Focal Onset Seizures
Interventions: JNJ-40411813, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more

Conditions: Healthy Volunteers
Interventions: DZD9008, Placebo; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
Interventions: Pexidartinib, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 19
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Sickle Cell Disease
Interventions: Tebapivat, Tebapivat Matched Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Farmington, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more

Search by objective public record fields.

A1Cantus vs. Placebo

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

Oral Nitrite Trial for Hypertension and Metabolic Syndrome

Sleep Hygiene Intervention on Undergraduate Students' Sleep and Stress

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)